LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Elenco Azioni・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Chiusa

SettoreSettore sanitario

67.34 3.11

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

64.25

Massimo

68.33

Metriche Chiave
By Trading Economics
Entrata	24M -167M
Vendite	40M 195M
EPS	-0.84
Margine di Profitto	-85.626
Dipendenti	834
EBITDA	75M -105M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+63.85% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-573M 13B
Apertura precedente	64.23
Chiusura precedente	67.34

Notizie sul Sentiment di mercato

By Acuity

43%

57%

139 / 344 Classifica in Healthcare

Bridgebio Pharma Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 giu 2026, 21:51 UTC

I principali Market Mover

Merlin Shares Rally After Defense Department's Design Review Wraps

4 giu 2026, 23:46 UTC

Discorsi di Mercato

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 giu 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 giu 2026, 23:42 UTC

Acquisizioni, Fusioni, Takeovers

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 giu 2026, 23:41 UTC

Acquisizioni, Fusioni, Takeovers

Energy Resources of Australia to Enter Trading Halt

4 giu 2026, 23:34 UTC

Discorsi di Mercato

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

4 giu 2026, 23:08 UTC

Discorsi di Mercato

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 giu 2026, 22:41 UTC

Discorsi di Mercato

Australia Shares Set to Rise at the Open -- Market Talk

4 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

4 giu 2026, 20:44 UTC

Acquisizioni, Fusioni, Takeovers

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 giu 2026, 20:16 UTC

Discorsi di Mercato

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 giu 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 giu 2026, 19:46 UTC

Discorsi di Mercato

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 giu 2026, 19:38 UTC

Discorsi di Mercato

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 giu 2026, 19:30 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 giu 2026, 18:47 UTC

Acquisizioni, Fusioni, Takeovers

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 giu 2026, 18:38 UTC

Utili

Money Quote: Tech Weakness in Context -- WSJ

4 giu 2026, 18:24 UTC

Utili

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 giu 2026, 17:09 UTC

Discorsi di Mercato

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 giu 2026, 16:58 UTC

Utili

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 giu 2026, 16:46 UTC

Discorsi di Mercato

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 giu 2026, 16:38 UTC

Utili

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

4 giu 2026, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

4 giu 2026, 16:13 UTC

Discorsi di Mercato

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 giu 2026, 16:11 UTC

Discorsi di Mercato

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 giu 2026, 15:56 UTC

Discorsi di Mercato

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Confronto tra pari

Modifica del prezzo

Bridgebio Pharma Inc Previsione

Obiettivo di Prezzo

By TipRanks

63.85% in crescita

Previsioni per 12 mesi

Media 107.29 USD 63.85%

Alto 157 USD

Basso 82 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Bridgebio Pharma Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

19 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a Bridgebio Pharma Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

139 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.